Literature DB >> 30911639

Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study.

Krishna Pillai1, Javed Akhter1, David L Morris1.   

Abstract

BACKGROUND: Pseudomyxoma peritonei (PMP) is difficult to treat. Intraperitoneal delivery of mucolytic solutions might potentially improve therapy, in addition to surgical cytoreduction and hyperthermic intraperitoneal chemotherapy.
METHODS: Comparison of mucolytic effect of two formulations (control: bromelain 300 µg/mL+N-Acetylcystein 250 mM; test: bromelain 200 µg/mL+200 mM cysteamine) in vitro on a mucin producing cell lines (HT29) and ex vivo on mucus obtained from 18 PMP patients. Mucin plugs were classified according to their density into three categories: hard, semi hard and soft. Simulation of peritoneal washing ex vivo using a closed heated circulating pump.
RESULTS: Solubilisation was faster with the test vs. the control formulation (90 vs. 180 min) for dissolving the soft mucin plugs (p < 0.05). The test solution was also more effective in dissolving the hard mucus plugs compared to control (82.5±2.74 % vs. 36.33±3.27 %). All mucin types disintegrated in simulated peritoneal washing. Cytotoxicity of the test solution on HT29 cell line was time-dependent.
CONCLUSIONS: The test formulation is more effective and faster than the control formulation in dissolving mucus plugs of various densities. Mucus plugs were all solubilised after 40 min in simulated peritoneal washing. This novel mucolytic formulation might pave the way for an effective and less invasive therapy of PMP in the future.

Entities:  

Keywords:  bromelain; cysteamine; disintegration; hardness index; mucin; mucolytic agents and intraperitoneal chemotherapy; pseudomyxoma peritonei

Year:  2017        PMID: 30911639      PMCID: PMC6405029          DOI: 10.1515/pp-2017-0013

Source DB:  PubMed          Journal:  Pleura Peritoneum        ISSN: 2364-768X


  28 in total

1.  KINETIC STUDIES OF BROMELAIN CATALYSIS.

Authors:  T INAGAMI; T MURACHI
Journal:  Biochemistry       Date:  1963 Nov-Dec       Impact factor: 3.162

2.  Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.

Authors:  Elizabeth M Murphy; Rosemary Sexton; Brendan J Moran
Journal:  Dis Colon Rectum       Date:  2007-01       Impact factor: 4.585

Review 3.  Glutathione in defense and signaling: lessons from a small thiol.

Authors:  Dale A Dickinson; Henry Jay Forman
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

4.  Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.

Authors:  Thomas J Miner; Jinru Shia; David P Jaques; David S Klimstra; Murray F Brennan; Daniel G Coit
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.

Authors:  P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2001-04       Impact factor: 4.424

6.  Sulforhodamine B colorimetric assay for cytotoxicity screening.

Authors:  Vanicha Vichai; Kanyawim Kirtikara
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Characterization of the acidic and basic limbs of a bell-shaped pH profile in the inhibitory activity of bromelain inhibitor VI.

Authors:  Ken-ichi Hatano; Yoriko Sawano; Takuya Miyakawa; Masaru Tanokura
Journal:  Biopolymers       Date:  2006-03       Impact factor: 2.505

Review 8.  Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress.

Authors:  J D Hayes; L I McLellan
Journal:  Free Radic Res       Date:  1999-10

Review 9.  The etiology, clinical presentation, and management of pseudomyxoma peritonei.

Authors:  Brendan J Moran; Thomas D Cecil
Journal:  Surg Oncol Clin N Am       Date:  2003-07       Impact factor: 3.495

10.  Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.

Authors:  R M Smeenk; M L F van Velthuysen; V J Verwaal; F A N Zoetmulder
Journal:  Eur J Surg Oncol       Date:  2007-05-23       Impact factor: 4.424

View more
  4 in total

1.  A novel method for potentiation of chemotherapy in soft tissue sarcomas with BromAc.

Authors:  Lillian Dong; Kevin Ke; Samina Badar; Ahmed H Mekkawy; Javed Akhter; Krishna Pillai; Carly J Carter; David L Morris
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

2.  Comparison of proteolytic, cytotoxic and anticoagulant properties of chromatographically fractionated bromelain to un-fractionated bromelain.

Authors:  Samina Badar; Mohamed Azarkan; Ahmed H Mekkawy; Javed Akhter; Krishna Pillai; Rachida El Mahyaoui; Kevin Ke; Lauren Cavanaugh; David L Morris
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study.

Authors:  Kevin Ke; Krishna Pillai; Ahmed H Mekkawy; Javed Akhter; Samina Badar; Sarah J Valle; David L Morris
Journal:  Discov Oncol       Date:  2021-08-16

4.  The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.

Authors:  Javed Akhter; Grégory Quéromès; Krishna Pillai; Vahan Kepenekian; Samina Badar; Ahmed H Mekkawy; Emilie Frobert; Sarah J Valle; David L Morris
Journal:  Viruses       Date:  2021-03-06       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.